Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMP-001 (vidutolimod), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system.
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMP-001, an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger body’s innate immune system to attack tumors in combination ...
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Regeneron Completes Acquisition of Checkmate Pharmaceuticals
Details : The acquisition strengthens Regeneron's portfolio of immuno-oncology candidates, by acquiring Checkmate's pipeline including lead candidate, CMP-001 (vidutolimod), an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 agonist delivered i...
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : $250.0 million
May 31, 2022
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University of Iowa Holden Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of this study is to determine the dose of CMP-001 (vidutolimod) that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity in patients with relapsed lymphoma who have failed at least one line of therapy.
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Iowa Holden Comprehensive Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Details : Regeneron's resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy.
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : $250.0 million
April 19, 2022
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Regeneron Pharmaceuticals
Deal Size : $250.0 million
Deal Type : Acquisition
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma.
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 15, 2020
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Longitude Capital
Deal Size : $85.0 million
Deal Type : Series C Financing
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
Details : Checkmate plans to use the proceeds from the financing to support the continued clinical development of CMP-001 in anti-PD-1 refractory melanoma as well as to pursue studies in additional indications, such as front-line melanoma and head and neck squamou...
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 06, 2020
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Longitude Capital
Deal Size : $85.0 million
Deal Type : Series C Financing
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CMP-001 in combination with pembrolizumab continues to demonstrate durable responses in anti-PD-1 refractory melanoma in ongoing trial.
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. FDA has granted Fast Track designation to its product candidate, CMP-001, a differentiated Toll-like receptor 9 (TLR9) agonist, in combination with a programmed death receptor 1 (PD-1) blocking antibody (nivolumab or pembrolizumab) for two developme...
Product Name : CMP-001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Vidutolimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable